Controlling cardiovascular risk factors and maintaining long-term disease remission mitigated the increased risk for ...

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) ...

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

“Incomplete lupus” is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

ALM-223 is under clinical development by Almirall and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

The presence of antiarrestin autoantibodies among patients with SLE is associated with an increased risk of developing HCQ-related retinal toxicity.

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

Discover a study where results suggest that patients with cutaneous lupus erythematosus may benefit from increased vigilance ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.